T-knife

T-knife Therapeutics develops novel T-cell receptor (TCR) engineered T-cell therapies designed to combat various cancers. The company leverages a proprietary humanized TCR mice platform to discover and optimize potent T-cell receptors. This platform enables the precise identification and targeting of specific tumor antigens, aiming to deliver highly effective immunotherapies, particularly for patients with solid tumors.

The company was founded in 2015 by Professor Thomas Blankenstein and Dr. Elisa Kieback, originating from their pioneering T-cell and immunology research. Their work, conducted at the Max Delbrück Center for Molecular Medicine and Charité in Berlin, provided the foundational insight into engineering T-cells to specifically recognize and eliminate cancer cells, leading to the formation of T-knife to translate these discoveries into clinical applications.

T-knife's therapeutic pipeline is focused on providing new options for cancer patients, with an initial emphasis on addressing the significant unmet needs in solid tumor indications. The company's vision is to advance the frontier of immunotherapy by developing a new generation of safe and efficacious T-cell-based medicines, ultimately striving to offer transformative treatment possibilities and improved prognoses for individuals facing severe oncological diseases.

High-Level Overview

T-knife Therapeutics is a clinical-stage biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-Ts) for solid tumors, leveraging proprietary platforms to create "supercharged" T cells with enhanced fitness, persistence, and tumor microenvironment resistance.[1][4][5] It targets cancer antigens like PRAME and MAGE-A1, serving patients with difficult-to-treat solid tumors by addressing limitations of existing immunotherapies through broad, deep, and durable responses; its lead candidate TK-6302 plans a Phase 1/2 trial in 2026 following a CTA submission in fall 2025.[1][4] With $187.2M in total funding, including a $110M round, T-knife shows strong growth momentum from its Berlin base, supported by top investors like RA Capital and Versant Ventures.[2][3]

Origin Story

T-knife emerged from decades of research at the Max Delbrück Center (MDC) for Molecular Medicine and Charité – Universitätsmedizin Berlin, where co-founder Professor Thomas Blankenstein and his team pioneered technology using humanized TCR (HuTCR) mouse models to identify high-affinity TCRs for cancer immunotherapy.[1][2] Founded in 2015 as an MDC spin-off by Blankenstein, Dr. Elisa Kieback, and Holger Specht (from IBB Beteiligungsgesellschaft), it transitioned to a limited liability company in 2018 with technology transfer support from Ascenion.[2][3] Early funding included €8M from Boehringer Ingelheim and Andera Partners in 2018, enabling a team of 15 and lab setup in Berlin-Buch; a €66M Series A in 2020 (part of $110M total) fueled pipeline expansion, including lead programs TK-8001 (MAGE-A1) and TK-6302 (PRAME).[2][3]

Core Differentiators

T-knife stands out in TCR-T development through integrated proprietary technologies for superior solid tumor efficacy:

• MyT Platform: High-throughput generation of fully human TCRs via HuTCR mice, yielding optimized affinity/specificity that evades human immune tolerance for better targeting of intracellular antigens.[2][5]
• Supercharged Enhancements: Combines costimulatory coreceptors (boosting CD4 cytotoxicity and persistence), TME-armoring switch receptors (blocking inhibitory signals, preventing exhaustion), and non-viral manufacturing (higher yields, memory phenotype retention).[1][4][5]
• Pipeline Focus: TCR-Ts like TK-6302 (PRAME) show multi-round tumor destruction in 3D models; ongoing IMAG1NE Phase 1/2 for TK-8001 demonstrates broad in vitro/in vivo activity superior to human-derived TCRs.[1][3][4]
• Scientific Pedigree: Backed by MDC/Charité origins, experienced leadership, and ~40 employees with $8.5M revenue trajectory.[3]

Role in the Broader Tech Landscape

T-knife rides the T cell therapy wave for solid tumors, where TCR-Ts expand beyond CAR-T's surface-antigen limits to target the full cancer proteome, amid surging demand for durable immunotherapies post-checkpoint inhibitors.[4][5] Timing aligns with synthetic biology advances enabling multi-enhancement "armoring," countering immunosuppressive TMEs that doom ~90% of solid tumor trials; market forces like aging populations and $100B+ oncology spend favor it.[1][5] As a Berlin biotech hub player, T-knife influences the ecosystem via MDC spinout model, attracting VC (EQT, RA Capital) and validating HuTCR tech for next-gen players.[2]

Quick Take & Future Outlook

T-knife's 2026 Phase 1/2 launches for TK-6302 and IMAG1NE readouts position it for proof-of-concept in PRAME/MAGE-A1 tumors, potentially unlocking blockbuster indications like ovarian, lung, and melanoma.[1][3][4] Trends like non-viral engineering and combo regimens with PD-1s will accelerate its path, with influence growing via partnerships or buyouts from big pharma seeking solid tumor breakthroughs. This MDC-born innovator exemplifies how platform tech can transform cancer care, delivering on T-knife's vision of curative TCR-Ts.[2][5]